Open in interactive viewer → charts, metric popovers & call review

TELA Bio's 90-Day Reset Is a Triage, Not a Turnaround

A new CEO cut costs and bought covenant relief, but PRS is still shrinking and the sales-force inflection has gone quiet
TELA · Earnings Call · 2026-11-10

A stabilization quarter, not a growth quarter

TELA Bio's third quarter arrived with a new CEO, a smaller cost base, and a freshly waived debt covenant. Revenue was $19 million, down 8% year over year. The U.S. hernia business grew sequentially and its unit volume grew both year over year and sequentially, while European growth came in at 18% and LIQUIFIX set a record with its customer base up 60% year to date. But OviTex PRS, the plastic and reconstructive surgery product, fell 20% year over year and 6% sequentially. That mix is the whole report: the hernia franchise is stabilizing, Europe is real, and PRS is still the hole. The market backdrop is ugly. TELA's stock is down 94% since late 2019, and the last 90 trading days show a 10.5% decline after a brief 101% three-week rally and a 38% six-week slide; the shares sit 43% below their September peak. At a $39 million market cap, the equity is an option on a recovery, not a consensus compounder. The company's own fundamentals from the last filed quarter show why: $19 million of quarterly revenue, an -58.1% operating margin, and a 126.6% liabilities-to-assets ratio. The latest filing predates the Q3 call, but the shape is clear. Heather Getz, 90 days into the CEO job, is trying to sell a reset rather than a rebound. The $17 million cost reduction plan cut headcount by about 20% and reduced operating expenses to $17.6 million from $21.4 million. Adjusted EBITDA loss improved 40% year over year and 56% sequentially to $3.4 million. The company ended with “$22.7 million in cash and cash equivalents” — Heather Getz · 2026-11-10. Perceptive also agreed to suspend testing of the minimum revenue covenant for two quarters. That is help, but it is not a clean bill of health.

PRS: the pilot that became the problem

The most revealing admission was about PRS. For several quarters, management framed the weakness as a concentration issue: a handful of high-volume surgeons had retired, taken maternity leave, or stepped away for personal reasons. On the August call, Jeff Blizard said plainly, “PRS is not a systemic issue.” — Jeffrey Blizard, President · 2026-08-10 Three months later, Getz described the problem differently: “some of the challenges that we have within that market are self-inflicted” — Heather Getz · 2026-11-10. The company had split out dedicated PRS reps, a pilot covering only six people in key cities, then pulled them back into the full sales bag. The rollback and retraining created a gap just as the concentrated surgeon community was already fragile. The current numbers show the cost of that experiment. “OviTex PRS revenue was down 20% year-over-year and 6% sequentially.” — Jeffrey Blizard · 2026-11-10 Management says the decline is concentrated in a limited number of markets, not broad across the organization. That may be true, but a concentrated customer base cuts both ways: it makes the product look stable when the key surgeons are active and makes it look broken when they are not. The clinical story is improving, with the largest PRS study accepted for publication in Reconstructive Surgery and lower odds of seroma formation versus a traditional biologic. But clinical evidence has a longer sales cycle than a rep bag can fix in one quarter.

The sales-force inflection goes quiet

The bigger contrast is with the company's own prior narrative. In March, management guided 2026 revenue growth of at least 8% and described the year as one of execution. In August, the call was built around 90-plus territory managers, a 40% new-rep cohort, and a six-to-nine-month productivity curve. Jim Hagen said on that call that TELA was looking at a “9- to 12-month ramp for reps” — Jim Hagen, Unknown (likely senior management or commercial leader) · 2026-08-10 to reach strong productivity. The implication was that the back half of 2026 would show an inflection point as those new rep cohorts matured. That vocabulary has largely vanished. On the Q3 call, Getz said the company has about 90 sales people globally and that “I'm still evaluating what that growth trajectory or ramp will look like” — Heather Getz · 2026-11-10. She would only commit to sequential improvement in Q4 and growth continuing into 2027. There was no formal revenue guidance, no reinstated 8% target, and no claim that the sales-force inflection had arrived. The top company keywords this quarter are not about rep productivity; they are about adjusted go-to-market strategy, core growth priorities, and a disciplined approach. That is what a company says when the old playbook needs more time.

While I believe we will see sequential improvement in Q4, this is not a 1-quarter fix. It is a multipronged, multi-quarter process.

Heather Getz · 2026-11-10
The operating leverage is real. The cost plan gives management a credible path to a $76 million to $78 million expense base in 2027, and Getz put the savings at “$76 million to $78 million range” — Heather Getz · 2026-11-10. But expense discipline cannot substitute for revenue. The company still faces the same bundling and market access barriers in U.S. hospitals that it has described for several quarters. Getz estimates that in accounts where TELA gets a fair shot, it can win 10% to 20% of the business. The problem is getting more accounts to that fair-shot status.

Balance sheet buys time, not conviction

The balance sheet is the constraint that makes the PRS and sales-force issues urgent. TELA is valued at 0.4x revenue and 0.6x gross profit, down roughly 97% from the 2020 peak multiples. The last filed quarter showed negative $25 million of effective net cash. The covenant suspension is a two-quarter bridge, not a cure. If the revenue recovery slips past the first half of 2027, the company will be back at the same financing question that has hung over the stock for years. There are optionality pieces. Liora, a fully reabsorbable surgical mesh, received FDA 510(k) clearance, and management said a commercial plan update will come in early 2027. That is too far away to matter for the current cash burn. The U.S. hernia business is close to returning to year-over-year growth, but Q4 faces the toughest comparison of the year. Europe and LIQUIFIX can help, but they are not yet large enough to offset a 20% decline in PRS. The story, then, is not that TELA Bio has turned. It is that a new CEO has bought time with cost cuts and a covenant waiver while admitting the commercial strategy was part of the problem. The stock is already priced for failure; the next two quarters need to show PRS stabilizing and U.S. hernia crossing back to year-over-year growth. Until then, the cost reduction is the only part of the reset that is fully visible in the numbers.